A Phase 4 interventional study of Opioids and No opioids in Postoperative Pain and Inguinal Hernia, sponsored by Clayton Petro. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Clayton Petro · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 329 studies testing opioids in Pain, Postoperative — 53 open to participants now, 65 under way, 6 of them phase 3. A drug class: Opioids · Pain, Postoperative.
Among the 329 studies testing opioids in Pain, Postoperative, this one is the 6th largest by planned enrollment, is one of 19 that started in 2023, is one of 145 in phase 4, reaches primary completion later than 43 of the 64 other live ones, and was the 246th registered.
5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →53 of the 329 studies testing opioids in Pain, Postoperative are open now, in 12 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
Tanta University · Sites in Egypt
Ages 21–60
Sohag University · Sites in Egypt
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Brandon Knopp · Sites in United States
Ages 18–120
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
329 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 42 · Phase 3 48 · Phase 4 145
First in 1996; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 904 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 84 across the 329 interventional studies. Of the 215 that completed or were terminated, 59 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 329 have an industry lead sponsor. The 10 most frequent:
Clayton Petro is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Clayton Petro has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
27 of the studies testing opioids in Pain, Postoperative that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT07227064Phase 3Medical University of South CarolinaMethadone in THA for Post-op Pain and Opioid Reduction | 2026-12-31 |
| NCT06996561Phase 3Dr. Asma Abdus SalamExploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management | 2027-01-01 |
| NCT07720739Sohag UniversityEfficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 329 studies testing opioids in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.
Patients presenting with primary or recurrent inguinal hernias, previously repaired in an open fashion, will be considered eligible to be enrolled in this study. Exclusion criteria include patients who cannot tolerate general anesthesia, opioids or NSAIDS, surgeries requiring extensive dissection/hernia sac reduction, or additional procedures, patients requiring inpatient admission postoperatively, and patients who are not able to understand and sign a written consent form. Surgeons will notify a study coordinator at the end of surgery for randomization. Patients will be randomized to opioids versus no opioids at the end of surgery and stratified based on unilateral versus bilateral inguinal hernia repair. The intervention will be not prescribing opioids post-operatively. If patients require prescription for opioids after randomization for uncontrolled pain for the no opioid group, the patient will remain in the intervention group and will be treat as intention to treat which will be recorded in REDCap®. All patients in the study will receive prescriptions for Acetaminophen and Ibuprofen. No other intraoperative or postoperative differences will occur between the two groups.
Baseline information, operative details, and 30-day outcomes are already captured within the ACHQC database, allowing for follow-up, and data capture with decreased effort outside of routine care. Randomization data will be captured and stored in REDCap®.
Baseline patient demographics will be obtained at initial patient recruitment, and baseline ACHQC questionnaires will be completed following patient recruitment. All operative details are already routinely collected and stored in the ACHQC database. Patient-reported quality of life will also be assessed at baseline and at 30 days using the EuraHS Quality Of Life survey tool, which is collected for all patients entered into the ACHQC as part of the ACHQC Inguinal Hernia Postoperative Assessment. Patients will be required to complete these forms at each clinic visit, or via telephone contact, as this is standard procedure for all patients entered into the ACHQC. At the time of the one-month follow-up clinic visits, a routine physical examination will be performed on all patients.
Outcomes to be investigated:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of care 5 tablets of Oxycodone (5mg) every 6 hours as needed for pain
Drug: Opioids
Standard of care
Other: No opioids
Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
Also known as: Opioid
Standard of care, patients will not receive a prescription for opioids.
Opioid refills/requests
The number of opioid prescription refills/requests will be compared between the two groups
Time frame: At the one month follow up visit
Postoperative pain
Postop pain will be assessed using the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity 3a scale scale between the two groups where higher scores mean worse pain
Time frame: At the one month follow up visit
Quality of life, pain, cosmesis
Quality of life, pain, and cosmetic outcomes will be assessed using the EuraHS (European registry for abdominal wall hernias) Quality of Life scale between the two groups where higher scores mean worse quality of life.
Time frame: At the one month follow up visit
Patient satisfaction
Overall patient satisfaction: patients will be asked if they are dissatisfied, neutral, or satisfied with respect to their postoperative pain management and the responses will be compared between the two groups
Time frame: At the one month follow up visit
Number of emergency room (ER)/clinic/urgent care visits for pain
The number of emergency room/clinic/urgent care visits for pain will be compared between the two groups
Time frame: At the one month follow up visit
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 47 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opioids
Clayton Petro